ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutations. ApoGen is building upon technologies developed at the University of Minnesota to develop drugs that block a key pathway that causes drug resistance. ApoGen’s drug discovery and development efforts are directed toward highly selective and potent small molecule inhibitors of the APOBEC family of enzymes, which are DNA cytosine deaminases and an important endogenous source of DNA mutations in cancer. ApoGen is based in Seatlle.


Team Members
more about
Cheryl Zimberlin
more about
Keno Gutierrez
Latest News Entry
ApoGen Biotechnologies Expands Series A Financing to $11 Million and Enhances Leadership Team

M Ventures Joins Existing Investors to Support Development of Novel Therapies Targeting Resistance to Cancer Therapy
Stephen Gwaltney and Peter de Vries Join Senior Scientific Management Team

all portfolio news